Neovii
Neovii is a Swiss company whose anti-T-lymphocyte globulin, Grafalon, is given before stem cell transplants to lower the risk of graft versus host disease.
Overview
Neovii, headquartered in Rapperswil-Jona, Switzerland, makes Grafalon (anti-T-lymphocyte globulin, previously ATG-Fresenius), a rabbit-derived polyclonal antibody used in conditioning before allogeneic haematopoietic stem cell transplantation to reduce graft versus host disease and rejection. It has led phase 3 transplant trials in leukaemia registered on ClinicalTrials.gov.
Similar pages
not linked directly; found by shared links- CompanyPhaxiam Therapeutics (formerly ERYtech Pharma)
Shares Acute lymphoblastic leukaemia and the tag ctgov-sponsor.
- CompanyOrca Biosystems
Shares Acute myeloid leukaemia and the tag ctgov-sponsor.
- CompanyTreadwell Therapeutics
Shares Acute myeloid leukaemia and the tag ctgov-sponsor.
- Companyargenx
Shares Acute myeloid leukaemia and the tag ctgov-sponsor.
- CompanyOncoVerity
Shares Acute myeloid leukaemia and the tag ctgov-sponsor.
- CompanyShenzhen TargetRx
Shares Acute lymphoblastic leukaemia, Acute myeloid leukaemia and the tag ctgov-sponsor.
- CompanyMolecular Partners
Shares Acute myeloid leukaemia and the tag ctgov-sponsor.
- CompanyCellectis S.A.
Shares Acute lymphoblastic leukaemia and the tag ctgov-sponsor.